To directly target MUC1 positive advanced pancreatic tumors and trigger neutrophil-mediated immune response, the binding capacity of this mAb in combination with a polysaccharide beta 1,3/1,6 glucan (derived from S.cerevisiae) as an immune stimulator with two drugs gemcitabine and Imprime PGG was evaluated [103]. Here, MUC1 is linked to pancreatic neoplasm.